Gossamer Bio Inc (NAS:GOSS)
$ 0.6981 -0.0036 (-0.51%) Market Cap: 158.19 Mil Enterprise Value: 34.78 Mil PE Ratio: 0 PB Ratio: 2.92 GF Score: 36/100

Gossamer Bio Inc at Bank of America Merrill Lynch Global Metals, Mining & Steel Conference Transcript

May 14, 2019 / 08:00PM GMT
Release Date Price: $19.29 (-4.65%)
Ying Huang
BofA Merrill Lynch, Research Division - Director in Equity Research

All right. Good afternoon, everyone. My name is Ying Huang, I'm the large cap biotech analyst here at BofA Merrill Lynch. We have our next presenting company, Gossamer Bio, which recently joined the rank of publicly traded companies. So congrats to both Bryan and Sheila here. So we do have Sheila Gujrathi, the CEO and founder of Gossamer Bio. We're also pleased to have -- well, we actually welcome Bryan back home, I guess I should say. Bryan Giraudo, the CFO, who used to be an employee here at Merrill Lynch.

With that, again, thank you for coming to Vegas and thank you for making the debut at BofA Health Care Conference here in Vegas. So I'm going to turn over the podium to maybe Sheila, who may have some bit of prepared remarks here, then we'll go into the fireside chat. Thank you, Sheila.

Sheila K. Gujrathi
Gossamer Bio, Inc. - Co-Founder, President, CEO & Director

Thank you. Thank you, Ying. I will probably go through a few slides and then I'm happy to answer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot